Eli Lilly is the oncology antibody developer's largest shareholder, while other investors include Celgene and EMS subsidiary Brace Pharma Capital.
Canada-based oncology biotherapeutics developer Zymeworks filed on Monday to raise up to $75m in an initial public offering in the US that will give pharmaceutical companies Eli Lilly, Celgene and EMS exits.
Zymeworks is developing multifunctional biotherapeutics, initially to treat cancer. Its lead product candidate, ZW25, is a dual-targeting antibody that will target a protein called HER2 that promotes growth of cancer cells.
The IPO proceeds will support a phase 1 clinical trial for ZW25 and possibly the start of…
